Literature DB >> 18836777

Risk of recurrence in surgically resected stage I adenocarcinoma of the lung: histopathologic and immunohistochemical analysis.

Sukki Cho1, Sook-Whan Sung, Sanghoon Jheon, Jin-Haeng Chung.   

Abstract

STUDY
OBJECTIVES: Stage I adenocarcinoma of the lung is the most common type of lung cancer. A better understanding of the histopathology and molecular biology of lung cancer might improve the capability to predict the outcome for any individual patient. The purpose of this study was to evaluate several histopathologic and molecular markers in order to assess their prognostic value in stage I adenocarcinoma.
METHODS: Fifty-five patients at the Seoul National University Bundang Hospital were enrolled in the study. Histopathologic factors and molecular markers were selected.
RESULTS: Multivariate analysis demonstrated that necrosis, lymphatic vessel invasion, E-cadherin, p53, and Ki-67 emerged as independent prognostic factors of recurrence. When patients were grouped according to low or high risk according to the number of factors involved, the difference in disease-free survival between these groups was statistically significant.
CONCLUSIONS: In resected stage I adenocarcinoma, necrosis, lymphatic vessel invasion, E-cadherin, and p53 have been identified as independent predictors of disease-free survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18836777     DOI: 10.1007/s00408-008-9116-4

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  24 in total

1.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

2.  Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance.

Authors:  S Kase; K Sugio; K Yamazaki; T Okamoto; T Yano; K Sugimachi
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

3.  A biological staging model for operable non-small cell lung cancer.

Authors:  G Cox; J L Jones; A Andi; D A Waller; K J O'Byrne
Journal:  Thorax       Date:  2001-07       Impact factor: 9.139

Review 4.  Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma.

Authors:  P Dalquen; G Sauter; J Torhorst; E Schultheiss; P Jordan; S Lehmann; M Solèr; P Stulz; M J Mihatsch; F Gudat
Journal:  J Pathol       Date:  1996-01       Impact factor: 7.996

5.  A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers.

Authors:  T A D'Amico; M Massey; J E Herndon; M B Moore; D H Harpole
Journal:  J Thorac Cardiovasc Surg       Date:  1999-04       Impact factor: 5.209

6.  Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population.

Authors:  C F Mountain; J M Lukeman; S P Hammar; D W Chamberlain; W F Coulson; D L Page; T A Victor; L H Weiland
Journal:  J Surg Oncol       Date:  1987-07       Impact factor: 3.454

7.  Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer.

Authors:  I G Duarte; B L Bufkin; M F Pennington; A A Gal; C Cohen; A S Kosinski; K A Mansour; J I Miller
Journal:  J Thorac Cardiovasc Surg       Date:  1998-03       Impact factor: 5.209

Review 8.  Survival in early-stage non-small cell lung cancer.

Authors:  J C Nesbitt; J B Putnam; G L Walsh; J A Roth; C F Mountain
Journal:  Ann Thorac Surg       Date:  1995-08       Impact factor: 4.330

9.  Risk factors for recurrence and unfavorable prognosis in patients with stage I non-small cell lung cancer and a tumor diameter of 20 mm or less.

Authors:  Naruyuki Kobayashi; Shinichi Toyooka; Junichi Soh; Kouichi Ichimura; Hiroyuki Yanai; Hiroshi Suehisa; Shuji Ichihara; Masaomi Yamane; Motoi Aoe; Yoshifumi Sano; Hiroshi Date
Journal:  J Thorac Oncol       Date:  2007-09       Impact factor: 15.609

10.  Accumulation of p53 protein correlates with a poor prognosis in human lung cancer.

Authors:  D C Quinlan; A G Davidson; C L Summers; H E Warden; H M Doshi
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

View more
  7 in total

1.  BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.

Authors:  Peter R Bucciarelli; Kay See Tan; Neel P Chudgar; Whitney Brandt; Joseph Montecalvo; Takashi Eguchi; Yuan Liu; Rania Aly; William D Travis; Prasad S Adusumilli; David R Jones
Journal:  J Thorac Oncol       Date:  2017-10-31       Impact factor: 15.609

2.  Prognostic significance of grading in lung adenocarcinoma.

Authors:  Justine A Barletta; Beow Y Yeap; Lucian R Chirieac
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860

Review 3.  Necrosis and apoptotic index as prognostic factors in non-small cell lung carcinoma: a review.

Authors:  Charalampos Gkogkou; Konstantina Frangia; Muhammad W Saif; Rodoula Trigidou; Konstantinos Syrigos
Journal:  Springerplus       Date:  2014-03-01

4.  Prognostic and clinicopathological significance of downregulated E-cadherin expression in patients with non-small cell lung cancer (NSCLC): a meta-analysis.

Authors:  Yan-Long Yang; Ming-Wu Chen; Lei Xian
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

5.  Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer.

Authors:  Wenwei Hu; Yang Yang; Longzhen Zhang; Jianxin Yin; Jingwei Huang; Lei Huang; Hua Gu; Gening Jiang; Jianmin Fang
Journal:  Cancer Med       Date:  2017-04-05       Impact factor: 4.452

6.  Clinicopathological significance and prognostic value of E-cadherin expression in non-small cell lung cancer: A protocol for systematic review and meta-analysis.

Authors:  Dong Chao; Gawei Hu; Qingxin Li
Journal:  Medicine (Baltimore)       Date:  2021-02-19       Impact factor: 1.817

7.  Clinical significance and role of lymphatic vessel invasion as a major prognostic implication in non-small cell lung cancer: a meta-analysis.

Authors:  Jun Wang; Baocheng Wang; Weipeng Zhao; Yan Guo; Hong Chen; Huili Chu; Xiuju Liang; Jingwang Bi
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.